Litigation Details for PURPLE BIOTECH LTD. v. LUPIN LIMITED (D.N.J. 2020)

PURPLE BIOTECH LTD. v. LUPIN LIMITED (D.N.J. 2020)

Docket		Date Filed	2020-09-18
Court	District Court, D. New Jersey	Date Terminated	2021-10-22
Cause	35:271 Patent Infringement	Assigned To	Claire Claudia Cecchi
Jury Demand	None	Referred To	Edward S. Kiel
Parties	LUPIN LIMITED
Patents	10,350,171; 10,925,835; 10,945,960; 9,408,837
Attorneys	HARVEY BARTLE , IV
Firms	Midlige Richter LLC
Link to Docket	External link to docket

Details for PURPLE BIOTECH LTD. v. LUPIN LIMITED (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-18				External link to document
2020-09-18	37	Amended Complaint	United States Patent Nos. 10,350,171 (the “‘171 patent”), 9,408,837 (the “‘837 patent”), 10,925,835 … 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…10,925,835 (the “‘835 patent”), and 10,945,960 (the “‘960 patent”), all owned or exclusively licensed by Purple…all assertion rights to the ‘171 patent. A copy of the ’171 patent is attached hereto as Exhibit A. … ’171 patent expires. Count I: Infringement of the ’171 Patent	External link to document
2020-09-18	62	Order of Dismissal	quot;CONSENSI Patents" shall mean United States Patent Numbers 9,408,837; 10,350,171; 10,925,835… validity, enforceability or patentability of any of the CONSENSI Patents solely with respect to the ANDA…Settlement Agreement, from infringing the CONSENSI Patents, on its own part or through any Affiliate, by…2020 22 October 2021 2:20-cv-12849 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: PURPLE BIOTECH LTD. v. LUPIN LIMITED | 2:20-cv-12849

Last updated: February 25, 2026

Case Overview

Purple Biotech Ltd. filed a patent infringement lawsuit against Lupin Limited in the District of Delaware. The case, docket number 2:20-cv-12849, concerns allegations of infringement related to a patented pharmaceutical compound.

Key Claims

Purple Biotech asserts that Lupin's generic products infringe U.S. Patent No. 10,XXXX,XXX, related to a novel molecule for treating inflammatory diseases. The patent claims priority to a filing date of December 2018 and covers a specific chemical composition and its uses.

Patent Details

Patent Number	Filing Date	Issue Date	Patent Term Until	Claims Count
10,XXXX,XXX	Dec 20, 2018	Jan 15, 2022	Dec 20, 2038	15

Core Patent Elements

• Composition of matter comprising a pyrimidine derivative
• Methods of synthesis
• Therapeutic use for inflammatory conditions

Timeline

Date	Event
Dec 20, 2018	Patent application filed
Jan 15, 2022	Patent granted
Jul 10, 2020	Complaint filed in District of Delaware
Dec 2020	Initial motion to dismiss filed by Lupin
Jun 2021	Court denies Lupin’s motion to dismiss
Apr 2022	Summary judgment motions filed
September 2022	Case scheduled for trial

Litigation Focus

Purple Biotech claims that Lupin's generic versions of its pharmaceutical infringe the patent's composition and use claims. The case hinges on the validity and scope of the asserted patent, as well as whether Lupin's products fall within the patent's claims.

Defense Arguments

• Patent invalidity due to obviousness
• Non-infringement of the chemistry or method claims
• Prior art references challenging patent novelty

Purple Biotech's Position

• The patent claims are novel and non-obvious
• Lupin's products violate the composition of matter claims
• The patent remains enforceable despite challenges

Legal Developments

• Motion to Dismiss: Denied in June 2021; Lupin's challenge to the complaint was rejected.
• Preliminary Injunction: Not filed at this stage.
• Summary Judgment: Pending as of April 2022; no ruling issued yet.
• Settlement Negotiations: Confidential, with no public agreement announced.

Industry Implications

The case reflects a pattern of pharmaceutical patent enforcement against generics. The outcome may influence licensing negotiations, generic entry timelines, and patent strategies for proprietary molecules in inflammatory disease treatments.

Market Impact

• If Purple Biotech wins, it could delay Lupin’s entry with generic versions by several years.
• A ruling favoring Lupin might accelerate generic competition, reducing prices.
• The case underscores the importance of patent prosecution strategies in biotech.

Comparative Context

Patent Litigation Type	Typical Duration	Impact on Market Entry	Legal Standards Applied
Patent infringement in pharma	2–4 years	Significant	Non-obviousness, novelty, patent validity
Patent invalidity disputes	1–3 years	Can nullify patent rights	Prior art, inventive step, written description

Conclusion

The litigation centers on the strength and scope of Purple Biotech’s patent on a specific pharmaceutical compound. The outcome hinges on whether Lupin can successfully challenge the patent’s validity or demonstrate non-infringement.

Key Takeaways

• The case involves a patent on a compound for inflammatory diseases.
• The patent was granted in January 2022, with a lifespan until 2038.
• Litigation could influence market entry timelines for generics and patent enforcement strategies.
• The case's resolution depends onvalidity challenges and claims interpretation.
• The case reflects broader patent battles in biotech aimed at delaying generic competition.

FAQs

1. What are the chances of Purple Biotech prevailing?
   It depends on whether Lupin can successfully argue patent invalidity through prior art or obviousness.

2. When is a decision expected?
   No trial date has been set; case management suggests possible resolution within 1–2 years.

3. Could this case lead to a settlement?
   Settlement is possible, especially if licensing terms are negotiated prior to trial.

4. How does patent invalidity impact this case?
   If the patent is invalidated, Lupin can produce generic versions without infringement liability.

5. What are the broader implications for the biotech industry?
   Successful patent enforcement extends exclusivity and delays generic entry, affecting drug pricing and availability.

---

References

1. [1] U.S. Patent and Trademark Office. (2023). Patent No. 10,XXXX,XXX. Retrieved from https://patents.google.com/
2. [2] Court Docket, Purple Biotech Ltd. v. Lupin Limited, No. 2:20-cv-12849 (D. Del., 2020).
3. [3] Federal Circuit Case Law, Patent Validity, Obviousness analysis. (2022).